Moreover, we found hypermethylation of p14ARF, RASSF1 and p16INK4A genes and cytokine signalling gene (SOCS1) significantly associated with poor overall survival of CML patients on imatinib therapy. This evidence concerns the gene CDKN2A and chronic myelogenous leukemia, BCR-ABL1 positive.